




RealRate

PHARMACEUTICAL 2018

China Pharma Holdings INC
Rank 138 of 332

China Pharma Holdings, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of China Pharma Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of China Pharma Holdings INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 64% points. The greatest weakness of China Pharma Holdings INC is the variable Assets, Current, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 299%, being 47% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	12,290
Cost of Goods Sold	10,744
Intangible Assets	399
Liabilities, Current	9,227
Liabilities, Non-Current	0
Other Assets	23,723
Other Compr. Net Income	0
Other Expenses	19,161
Other Liabilities	7,654
Other Net Income	-475
Other Revenues	13,212
Property and Equipment	23,541
Research and Development	90
Selling, General and Administrative Expense	2,020

Output Variable	Value in 1000 USD
Assets	59,953
Liabilities	16,882
Expenses	32,015
Revenues	13,212
Stockholders Equity	43,071
Net Income	-19,278
Comprehensive Net Income	-19,278
BaseVar	61,268
ECR before LimitedLiability	194%
Economic Capital Ratio	299%